CN107308181A - Treat the compound medicinal formulation of refractory hypertension - Google Patents
Treat the compound medicinal formulation of refractory hypertension Download PDFInfo
- Publication number
- CN107308181A CN107308181A CN201710585463.2A CN201710585463A CN107308181A CN 107308181 A CN107308181 A CN 107308181A CN 201710585463 A CN201710585463 A CN 201710585463A CN 107308181 A CN107308181 A CN 107308181A
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- compound
- hypertension
- refractory hypertension
- captopril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of compound medicinal formulation for treating refractory hypertension, mainly it is made by the component of following portions by weight：GL-B 50~500, nifedipine 5~10, captopril 12.5~50, Hydrochioro 10~50, atenolol 12.5~100.The present invention first compounds GL-B and a variety of drugs for hypertension of conventional multi-joint therapy, a kind of compound preparation that can conveniently take is made, play the Synergistic Hypotensive Effects and its beneficial effect of mutual mitigation/counteracting side effect of GL-B and 4 kinds of medicines, significantly improve the compliance of refractory hypertension patient's Drug adherence, obtain the blood pressure level of substantially reduction refractory hypertension, even some patientss have reached controlling of blood pressure therapeutic effect up to standard, to simplify refractory hypertension patient medication, effectively reduce blood pressure level, there is provided a kind of compound blood pressure reducing novel drugs conveniently taken.
Description
Technical field
The present invention relates to field of medicaments, more particularly to a kind of compound medicinal formulation for treating refractory hypertension.
Background technology
Common patients with hypertension can be effectively controlled by conventional therapy blood pressure, but have some patientss use
Its blood pressure of conventional therapy can not be effectively controlled, and such hypertension is commonly referred to as refractory hypertension.It is newest
Hyperpietic's sample population research is shown：China's Hypertensive Population, uses more than the 3 kinds antihypertensive drugs including diuretics
It can not still reach mark blood pressure is accounted for 11.7%, can not still reach mark blood pressure is accounted for 0.8% using more than 5 kinds antihypertensive drugs.It means that
Even with existing various antihypertensive drugs, the hyperpietic for still having 12.5% has suffered from refractory hypertension and blood pressure can not
Control.
NO (nitric oxide) is a kind of vasodilator, and NO reduces it with capillary density, capillary diameter, blood pressure
Between be in obvious positive correlation.Increasing for NO concentration in plasma is hypertensive patient's Marjoram Extract, peripheral resistance declines, microcirculation changes
One of the reason for kind and blood pressure is reduced.
Research also shows that the antihypertensive drugs species and compliance that patient takes are closely related, patient psychological often due to
The side effect of frightened multi-medicament is without by medication, the types of medicines of doctor formula is more, and the compliance of patient is poorer.Instead
It, with the reduction of types of medicines, the compliance of patient is better.Research has shown that, simplifies medicine (species and the frequency that reduce medicine)
Can improve 8-19.6% compliance (traditional Chinese medical science is printed in curative compliance and refractory hypertension, Vol.2016. (51) .Na.12,
China-Japan Friendship Hospital Chen Li etc.).Therefore, the single antihypertensive drugs of 3 kinds or more than 3 kinds is combined into a kind of compound preparation, can be from
It is psychological to make patient feel to take a kind of antihypertensive drugs, but be actually to have taken multi-medicament and obtained equivalent a variety of medicines
The equivalent collaboration decompression of thing and its effect for side effect of cancelling out each other.Therefore can improve refractory hypertension patient compliance,
Standardized drug and antihypertensive effect.
The content of the invention
The purpose of the present invention is to provide the compound medicine that a kind of curative effect significantly treats refractory hypertension regarding to the issue above
Thing preparation.
The present invention realizes that the technical scheme of its purpose is：
A kind of compound medicinal formulation for treating refractory hypertension, is mainly made by the component of following portions by weight：Ganoderma lucidum
Polysaccharide 50~500, nifedipine 5~10, captopril 12.5~50, Hydrochioro 10~50, atenolol 12.5~100.
Above-mentioned compound medicinal formulation is mainly made by the component of following portions by weight：GL-B 50~300, nifedipine
5~10, captopril 18~30, Hydrochioro 18~30, atenolol 18~50.
Above-mentioned compound medicinal formulation is mainly made by the component of following portions by weight：GL-B 50~100, nifedipine
5~10, captopril 18~30, Hydrochioro 18~30, atenolol 18~50.
Preferably, above-mentioned compound medicinal formulation is mainly made by the component of following portions by weight：GL-B 50~
100th, nifedipine 10, captopril 25, Hydrochioro 25, atenolol 25.
Preferably, above-mentioned compound medicinal formulation is mainly made by the component of following portions by weight：GL-B 75, nitre
Benzene Horizon 10, captopril 25, Hydrochioro 25, atenolol 25.
In the above-mentioned technical solutions, the consumption of nifedipine, captopril, Hydrochioro and atenolol be at present this four
Conventional amount used of the medicine in treatment hypertension is planted, the use of joint GL-B can be such that refractory hypertension is effectively controlled
Treat.
In the above-mentioned technical solutions, the compound medicinal formulation of described treatment refractory hypertension is by the component and pharmacy
Upper acceptable carrier composition.
The compound medicinal formulation is tablet or capsule.
Research finds that GL-B is to be a kind of safe to eat and can improve the plant of drug for hypertension antihypertensive effect
Extract.Clinical observation is shown, nifedipine is taken combining, captopril, Hydrochioro, a variety of conventional medicines such as atenolol
It when thing treatment refractory hypertension is invalid, plus can not only be reduced blood pressure with GL-B, and microcirculation can also be improved.Further
Studies have shown that add and substantially increased with NO (nitric oxide) concentration of patient's blood plasma after GL-B, GL-B promotes huge
Phagocyte discharges NO to be strengthened in dose dependent, and can make the perfusion of microcirculation increases.By increasing capilary pipe button loop density, increase
Capilary bore, reduction blood viscosity, reduction blood flow resistance, so as to reduce pressure of the blood flow to vascular wall, are obtained
Obtain the effect that big arteriole pressure (including systolic pressure and diastolic pressure) capillary pressure is decreased obviously.Therefore, for using taking nitre
During more than the 4 kinds drug therapy refractory hypertensions such as benzene Horizon, captopril, Hydrochioro, atenolol, increase GL-B
So that NO concentration in plasma substantially increases and the improvement to microcirculation and blood pressure becomes apparent from, more stable.
The invention has effective effect that：GL-B and a variety of drugs for hypertension of conventional multi-joint therapy are answered first
Match somebody with somebody, a kind of compound preparation that can conveniently take is made, for effectively treating refractory hypertension.Avoid patient per's medication
Shi Bixu carefully calculates the quantity of multi-medicament and the trouble of dosage, be especially that of avoiding patient caused by consciously or unconsciously this 4
The situation for missing or wrongly taking of certain medicine in kind of medicine, realizes the Normalization rule of 4 kinds of medicines, play GL-B with this 4
Plant the Synergistic Hypotensive Effects of medicine and its beneficial effect of mutual mitigation/counteracting side effect, hence it is evident that improve refractory hypertension
The compliance of patient's Drug adherence, obtains the blood pressure level of substantially reduction refractory hypertension, or even some patientss reach
Controlling of blood pressure therapeutic effect up to standard, to simplify refractory hypertension patient medication, effectively reducing blood pressure that there is provided one kind for level
The compound blood pressure reducing novel drugs conveniently taken.
Embodiment
Embodiment 1
The randomized controlled trial of compound preparation (every contains GL-B 75mg) curative effect of the present invention
1 medicine preparation
Experimental drug：Plus GL-B Compound Reserpine, the every nifedipine 10mg+ Kato of 75mg+ containing GL-B is general
Sharp 25mg+ Hydrochioros 25mg+ atenolols 25mg.
Compare medicine：Nothing plus GL-B Compound Reserpine, the every captopril 25mg+ hydrogen chlorine of 10mg+ containing nifedipine
Thiazine 25mg+ atenolols 25mg.
2 clinical datas
2.1 diagnostic criteria
Press《Chinese hypertension prevention and control guide》Diagnostic criteria, essential hypertension (EH) patient through it is conventional with taking nitre benzene
More than three kinds of medicines such as flat, captopril, Hydrochioro, atenolol one month, blood pressure can not still be down to 18.0/12.0
(140/90mmHg, 1mmHg=0.133kPa) following person, is diagnosed as refractory hypertension.2.3 general information
Meet above-mentioned diagnostic criteria case 60, male 37, female 23.It is the oldest 76 years old, minimum 42 years old.High blood pressure
History is most long 35 years, most short 2 years.
2.3.1 curative effect determinate standard
According to defending what planning commission issued《Clinical drug studies guideline》Curative effect is divided into：It is effective：Diastole drops
20mmHg declines 10mmHg and is down to control targe value；Effectively：Diastolic pressure is declined by less than 10mmHg but has reached control targe
Value, or decline 10~19mmHg, such as shrink more than drops 30mmHg for simple systolic hypertension；It is invalid：It is not up to above-mentioned
Standard.
2.3.2 treatment method
Treatment group：Randomly select 30 patients and take experimental drug (GL-B+nifedipine+card in the present embodiment
Top's profit+Hydrochioro+atenolol compound hypertension pill), each one, three times a day.
Control group：Randomly select 30 patients and take control medicine (nifedipine+captopril+hydrogen in the present embodiment
Chlorothiazide+atenolol compound hypertension pill), each one, three times a day.
2.4 statistical procedures
As a result represented with average ± standard deviation (x ± s), examined with t and carry out significance test, P≤0.05 is to have statistics
Learn meaning.
3 results
1) treatment group：Take plus 30 patients of Compound Reserpine of GL-B treat 8 weeks, wherein, 26 controlling of blood pressure
Below 140/90mmHg, total effective rate 83.33%.2 patients give haemodialysis because merging renal insufficiency, potassemia
Controlling of blood pressure is in below 140/90mmHg after treatment, and 3 patients do not drop to below 140/90mmHg still through above-mentioned treatment blood pressure.
2) control group：30 patients of Compound Reserpine for taking no GL-B treat 8 weeks, and blood pressure is preceding without substantially with treatment
Difference, P ＞ 0.05.
Blood pressure, hemorheology, micro-cycle measurement change are shown in Table 1, table 2, table 3, table 4, table 5 before and after two groups of treatments.
As seen from Table 1, the patient of the treatment group for the Compound Tablet for adding GL-B is taken, after the treatment, its blood pressure is had
Effect reduction；And the refractory hypertension patient of the control group for the Compound Tablet for not adding GL-B is taken, its blood pressure is before and after medication
Compared to not there is significant change, fail to be effectively controlled.
Increase from the result of table 2, plus with after GL-B, capilary pipe button loop bar digital display writes, bore is significantly increased, and this must
So cause the blood of equivalent more smooth by the flowing velocity of capilary, reduce the blood flow resistance of capilary and produce
Reduce effect of the blood flow to vascular wall pressure.This is probably that GL-B collaboration other drugs increase the machine of antihypertensive effect
One of reason.
From the result of table 3, plus with after GL-B, blood viscosity, haemocyte deposition, erythrocyte sedimentation rate index are significantly reduced, this
Necessarily cause the blood of equivalent more smooth by the flowing velocity of capilary, alleviate the blood flow resistance of capilary and produce
Effect of the raw reduction blood flow to the pressure of vascular wall.This is probably GL-B collaboration other drugs increase antihypertensive effect
One of mechanism.
As seen from Table 4, the NO concentration of patient's blood plasma for the treatment of group substantially increases after treatment, can increase the perfusion of microcirculation
Plus, at the same time big arteriole pressure (including systolic pressure and diastolic pressure) capillary pressure is decreased obviously.Therefore, for taking nitre benzene
When Horizon, captopril, Hydrochioro, atenolol therapeutic alliance refractory hypertension, GL-B is added so that blood plasma NO
Concentration substantially increases and the improvement to microcirculation and blood pressure becomes apparent from, more stable.
The treatment Patients Before And After blood pressure of table 1 (kPa)
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
The medicine of table 2 influences on hypertensive patient's microcirculation of nail rugae
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
The medicine of table 3 is sexually revised to the hemorheology of hypertensive patient
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
Table 4 plus the change with GL-B Plasma Before And After NO concentration (umol/) L
| Group | n | Before medication | After medication |
| Plus GL-B treatment group | 30 | 7.90±3.43 | 11.98±5.15* |
| Without GL-B control group | 30 | 7.54±3.07 | 6.67±3.36 |
* P ＜ 0.05, with being compared before administration
Correlation between the blood plasma NO of table 5 and plasma viscosity, blood glucose, red blood cell speed, capillary density
As a result：It is difficult that GL-B, nifedipine, captopril, Hydrochioro, atenolol compound preparation can simplify treatment
The medication fussy degree of the property controlled hypertension, can improve the compliance of the multi-joint therapy of patient's specification application hypertension drug, effectively carry
The efficacy of antihypertensive treatment of high conventional multi-joint drug therapy treatment refractory hypertension.
Embodiment 2
The randomized controlled trial of compound preparation (every contains GL-B 500mg) curative effect of the present invention
1 medicine preparation
Experimental drug：Plus GL-B Compound Reserpine, the every nifedipine 10mg+ Kato of 500mg+ containing GL-B is general
Sharp 25mg+ Hydrochioros 25mg+ atenolols 25mg.
Compare medicine：Nothing plus GL-B Compound Reserpine, the every captopril 25mg+ hydrogen chlorine of 10mg+ containing nifedipine
Thiazine 25mg+ atenolols 25mg.
2 clinical datas
2.1 diagnostic criteria
Be the same as Example 1.
2.3 general information
Meet above-mentioned diagnostic criteria case 60, male 43, female 17.It is the oldest 73 years old, minimum 46 years old.High blood pressure
History is most long 32 years, most short 5 years.
2.3.1 curative effect determinate standard
Be the same as Example 1.
2.3.2 treatment method
Treatment group：Randomly select 30 patients and take experimental drug (GL-B+nifedipine+card in the present embodiment
Top's profit+Hydrochioro+atenolol compound hypertension pill), each one, three times a day.
Control group：Randomly select 30 patients and take control medicine (nifedipine+captopril+hydrogen in the present embodiment
Chlorothiazide+atenolol compound hypertension pill), each one, three times a day.
2.4 statistical procedures
As a result represented with average ± standard deviation (x ± s), examined with t and carry out significance test, P≤0.05 is to have statistics
Learn meaning.
3 results
1) treatment group：Take plus 30 patients of Compound Reserpine of GL-B treat 8 weeks, wherein, 26 controlling of blood pressure
Below 140/90mmHg, total effective rate 86.67%.2 patients give blood because merging the phase of chronic kidney 1, potassemia
Controlling of blood pressure is in below 140/90mmHg after dialysis treatment, 2 patients through above-mentioned treatment blood pressure do not drop to still 140/90mmHg with
Under.
2) control group：30 patients of Compound Reserpine for taking no GL-B treat 8 weeks, and blood pressure is preceding without substantially with treatment
Difference, P ＞ 0.05.
Blood pressure, hemorheology, micro-cycle measurement change are shown in Table 6, table 7, table 8, table 9 before and after two groups of treatments.
The treatment Patients Before And After blood pressure of table 6 (kPa)
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
The medicine of table 7 influences on hypertensive patient's microcirculation of nail rugae
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
The medicine of table 8 is sexually revised to the hemorheology of hypertensive patient
* P ＜ 0.05, * * P ＜ 0.01, with being compared before administration
Table 9 plus the change with GL-B Plasma Before And After NO concentration (umol/) L
| Group | n | Before medication | After medication |
| Plus GL-B treatment group | 30 | 7.89±3.33 | 12.78±4.75* |
| Without GL-B control group | 30 | 7.52±3.09 | 6.62±3.26 |
* P ＜ 0.05, with being compared before administration
As a result：It is difficult that GL-B, nifedipine, captopril, Hydrochioro, atenolol compound preparation can simplify treatment
The medication fussy degree of the property controlled hypertension, can improve the compliance of the multi-joint therapy of patient's specification application hypertension drug, effectively carry
The efficacy of antihypertensive treatment of high conventional multi-joint drug therapy treatment refractory hypertension.
Claims (7)
1. a kind of compound medicinal formulation for treating refractory hypertension, it is characterised in that the main component by following portions by weight
It is made：GL-B 50~500, nifedipine 5~10, captopril 12.5~50, Hydrochioro 10~50, atenolol
12.5~100.
2. the compound medicinal formulation of refractory hypertension is treated as claimed in claim 1, it is characterised in that mainly by following heavy
The component for measuring number is made：GL-B 50~300, nifedipine 5~10, captopril 18~30, Hydrochioro 18~30,
Atenolol 18~50.
3. the compound medicinal formulation of refractory hypertension is treated as claimed in claim 1, it is characterised in that mainly by following heavy
The component for measuring number is made：GL-B 50~100, nifedipine 5~10, captopril 18~30, Hydrochioro 18~30,
Atenolol 18~50.
4. the compound medicinal formulation of refractory hypertension is treated as claimed in claim 1, it is characterised in that mainly by following heavy
The component for measuring number is made：GL-B 50~100, nifedipine 10, captopril 25, Hydrochioro 25, atenolol 25.
5. the compound medicinal formulation of refractory hypertension is treated as claimed in claim 1, it is characterised in that mainly by following heavy
The component for measuring number is made：GL-B 75, nifedipine 10, captopril 25, Hydrochioro 25, atenolol 25.
6. a kind of compound medicinal formulation of the treatment refractory hypertension described in any one of claim 1 to 5, it is characterised in that
Said preparation is made up of the component and pharmaceutically acceptable carrier.
7. the compound medicinal formulation of refractory hypertension is treated as claimed in claim 6, it is characterised in that the compound medicine
Preparation is tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710585463.2A CN107308181A (en) | 2017-07-18 | 2017-07-18 | Treat the compound medicinal formulation of refractory hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710585463.2A CN107308181A (en) | 2017-07-18 | 2017-07-18 | Treat the compound medicinal formulation of refractory hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107308181A true CN107308181A (en) | 2017-11-03 |
Family
ID=60178642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710585463.2A Pending CN107308181A (en) | 2017-07-18 | 2017-07-18 | Treat the compound medicinal formulation of refractory hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107308181A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771497A (en) * | 2019-03-22 | 2019-05-21 | 福建省南平市人民医院（福建省南平市中医院） | A kind of blood pressure decreasing capsule and preparation method |
| CN110755505A (en) * | 2019-12-05 | 2020-02-07 | 福建省南平市人民医院（福建省南平市中医院） | Medicine for treating hypertension and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695623A (en) * | 2005-04-27 | 2005-11-16 | 葛荣专 | United compound medicines in small dose for treating hypertension |
| CN1864687A (en) * | 2005-10-30 | 2006-11-22 | 山东瑞阳制药有限公司 | Compound blood pressure reducing preparation |
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
| CN101935358A (en) * | 2010-09-10 | 2011-01-05 | 上海市农业科学院 | Ganoderma lucidum polysaccharide and preparation method thereof |
| US20120171150A1 (en) * | 2011-01-05 | 2012-07-05 | Dr. Benjamin S. Metelits | Ion Bonding Pharmaceutical Composition |
| CN106432136A (en) * | 2016-06-30 | 2017-02-22 | 中国药科大学 | Hydrochlorothiazide and atenolol co-amorphous system and preparation method thereof |
-
2017
- 2017-07-18 CN CN201710585463.2A patent/CN107308181A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695623A (en) * | 2005-04-27 | 2005-11-16 | 葛荣专 | United compound medicines in small dose for treating hypertension |
| CN1864687A (en) * | 2005-10-30 | 2006-11-22 | 山东瑞阳制药有限公司 | Compound blood pressure reducing preparation |
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
| CN101935358A (en) * | 2010-09-10 | 2011-01-05 | 上海市农业科学院 | Ganoderma lucidum polysaccharide and preparation method thereof |
| US20120171150A1 (en) * | 2011-01-05 | 2012-07-05 | Dr. Benjamin S. Metelits | Ion Bonding Pharmaceutical Composition |
| CN106432136A (en) * | 2016-06-30 | 2017-02-22 | 中国药科大学 | Hydrochlorothiazide and atenolol co-amorphous system and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邵林: "顽固性高血压的降压药物治疗分析", 《中国医药指南》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771497A (en) * | 2019-03-22 | 2019-05-21 | 福建省南平市人民医院（福建省南平市中医院） | A kind of blood pressure decreasing capsule and preparation method |
| CN110755505A (en) * | 2019-12-05 | 2020-02-07 | 福建省南平市人民医院（福建省南平市中医院） | Medicine for treating hypertension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1157737A (en) | ''Shanzhiai'' oral dosage | |
| CN104127661B (en) | Traditional Chinese medicine oral liquid for treating non-small cell lung cancer | |
| US20210085638A1 (en) | Terpene Control in Scaleable Cannabinoid Medicinal Formulations | |
| CN107308181A (en) | Treat the compound medicinal formulation of refractory hypertension | |
| CN102008710B (en) | Lisinopril-containing compound preparation for treating hypertension | |
| CN108635511A (en) | Radix Paeoniae Alba and dendrobium candidum are preparing the application process in treating hypertension drug | |
| CN108653581A (en) | The method for preparing treatment hypertension drug with Radix Paeoniae Alba, dendrobium candidum and Irbesartan | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| Alfano et al. | Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19 | |
| Dong et al. | Role of methadone in extracorporeal membrane oxygenation: Two case reports | |
| CN105326840B (en) | A kind of combination medicine containing qinghaosu | |
| CN111437362B (en) | Traditional Chinese medicine composition for adjuvant treatment of middle and late intestinal cancer and preparation method and application thereof | |
| CN103315987B (en) | A kind of pharmaceutical composition for treating epilepsy | |
| CN103301115B (en) | A kind of pharmaceutical composition for treating epilepsy | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN103315989B (en) | A kind of pharmaceutical composition | |
| CN108498570A (en) | A kind of Chinese medicine compound prescription and preparation method thereof for anti-idiopathic pulmonary fibrosis | |
| CN100364592C (en) | Medicine for treating diabetes | |
| CN103301124B (en) | A kind of pharmaceutical composition for treating epilepsy | |
| CN105168888B (en) | It is a kind of for treating the Chinese medicine composition and application thereof of fash caused by molecular targeted agents | |
| CN116270674A (en) | Application of Manacastine in relieving toxic and side effects of oxaliplatin | |
| CN111450175A (en) | Combined medicine or medicine box product for treating gastrointestinal tract reaction after chemotherapy and application | |
| Xia | Relevant Factors of Delayed Recovery after General Anesthesia and Exploration of the Countermeasures | |
| Sacks et al. | 1158: PLASMAPHERESIS SIGNIFICANTLY REDUCES SERUM AMLODIPINE LEVELS FOLLOWING INTENTIONAL OVERDOSE | |
| CN113368140A (en) | Application of spirulina in preparation of product for preventing and treating leukopenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171103 |